SEC Company Response from Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260) (FBIO) — Jul 19, 2019
Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260)
Date: July 19, 2019 · CIK: 0001429260 · Accession: 0001144204-19-035206
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226089
Letter
90 Park Avenue
New York, NY 10016
212-210-9400
Fax: 212-922-3995
www.alston.com
Mark F. McElreath Direct Dial: 212-210-9595 Email: mark.mcelreath@alston.com
July 19, 2019
Securities and Exchange Commission
Department of Corporation Finance
Washington, D.C. 20549
Attn: Mr. Jeffrey Gabor
Via: EDGAR Submission
Re: Fortress Biotech, Inc.
Registration Statement on Form S-3
Filed July 6, 2018
File No. 333-226089
Ladies and Gentlemen:
On behalf of our client, Fortress Biotech, Inc. (the “Company”), we hereby request that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:15 p.m. (ET) on July 23, 2019 or as soon as practicable thereafter, pursuant to Rule 461 of the Securities Act of 1933, as amended.
We, on behalf of the Company, acknowledge that (i) should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact me with any questions or comments at 212-210-9595. Thank you for your assistance with this filing.
Alston & Bird LLP www.alston.com
Atlanta | Beijing | Brussels | Charlotte | Dallas | Los Angeles | New York | Research Triangle | San Francisco | Silicon Valley | Washington, D.C.
Sincerely,
/s/ Mark F. McElreath
Show Raw Text
CORRESP
1
filename1.htm
90 Park Avenue
New York, NY 10016
212-210-9400
Fax: 212-922-3995
www.alston.com
Mark F. McElreath
Direct Dial: 212-210-9595
Email: mark.mcelreath@alston.com
July 19, 2019
Securities and Exchange Commission
Department of Corporation Finance
Washington, D.C. 20549
Attn: Mr. Jeffrey Gabor
Via:
EDGAR Submission
Re:
Fortress Biotech, Inc.
Registration Statement on Form S-3
Filed July 6, 2018
File No. 333-226089
Ladies and Gentlemen:
On behalf of our client,
Fortress Biotech, Inc. (the “Company”), we hereby request that the effective date for the Registration Statement referred
to above be accelerated so that it will be declared effective at 4:15 p.m. (ET) on July 23, 2019 or as soon as practicable thereafter,
pursuant to Rule 461 of the Securities Act of 1933, as amended.
We, on behalf of the
Company, acknowledge that (i) should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare
the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii)
the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective,
does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii)
the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person
under the federal securities laws of the United States.
Please contact me with
any questions or comments at 212-210-9595. Thank you for your assistance with this filing.
Alston & Bird LLP
www.alston.com
Atlanta | Beijing | Brussels | Charlotte | Dallas | Los Angeles
| New York | Research Triangle | San Francisco | Silicon Valley | Washington, D.C.
Sincerely,
/s/ Mark F. McElreath
Mark F. McElreath
Partner